Cholera
64
6
6
48
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.1%
2 terminated out of 64 trials
96.0%
+9.4% vs benchmark
33%
21 trials in Phase 3/4
21%
10 of 48 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 48 completed trials
Clinical Trials (64)
Single Dose Azithromycin to Prevent Cholera in Children
Cholera Control by Case-area Targeted Interventions (CATIs)
Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera
Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7)
Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea
Vaccine- and Infection-derived Correlates of Protection for Cholera
Immunologic Responses to a Live Attenuated Oral Cholera Vaccine
Preventative Intervention for Cholera for 7 Days
Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)
Simulation Based Training In Medical Students
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
Impact Study of Cholera Vaccination in Endemic Areas - Clinical Surveillance
Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change
Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi
Co-administration Study of OCV, TCV and MR
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200